Abstract 681
Background
Red blood cell distribution width (RDW) is a parameter measured in blood sample tests that reflects the variation in the volume of erythrocytes and used to differentiate an anemic state. The RDW has been used to predict a poor survival in various types of cancer; however, the prognostic impact of the RDW in resected pathological stage I non-small cell lung cancer (NSCLC) patients remains to be elucidated.
Methods
A total of 273 patients with resected pathological stage I NSCLC were included in this study. The cut-off value of RDW was set at 14.5, which was the upper limit of the normal range of the RDW. The controlling nutritional status (CONUT) score, which was calculated by the albumin, cholesterol and the lymphocyte count, was also investigated.
Results
Among 273 patients, 34 (12.5%) were RDW-high, while 239 (87.5%) were RDW-low. RDW-high was significantly associated with a lower body mass index (P < 0.01), a lower level of hemoglobin (P < 0.01), a higher level of C-reactive protein (P < 0.01), and a high CONUT score (P = 0.03) than RDW-low. Patients with RDW-high exhibited significantly shorter recurrence-free and overall survivals (RFS and OS, respectively) than those with RDW-low (P < 0.01 and P < 0.01, respectively). Multivariate analyses showed that the RDW was an independent prognostic factor for both the RFS and OS (RFS, hazard ratio [HR]: 2.16, 95% confidence interval [CI]: 1.14-3.95, P = 0.02; OS, HR: 2.44, 95% CI: 1.28-4.49, P < 0.01).
Conclusions
The RDW was shown to be a potent prognosticator for the RFS and OS in resected pathological stage I NSCLC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4615 - Proteomic Profiling Identifies Molecular Basis of Adverse Event to BPM31510 Exposure: Rationale for Comprehensive Molecular Pharmacodynamics (PD) in Phase 1 Clinical Trial Design
Presenter: Vivek Subbiah
Session: Poster Display session 1
Resources:
Abstract
5052 - Identification of first-in-class, naturally occurring LAG3 checkpoint inhibitor
Presenter: Gennady Bratslavsky
Session: Poster Display session 1
Resources:
Abstract
5336 - Are Epigenetic therapies modifying sensitivity to conventional chemotherapy?
Presenter: Alexandra Bizot
Session: Poster Display session 1
Resources:
Abstract
5739 - Oncogenic mutations at the dimer interface of EGFR lead to formation of covalent homo-dimers and allosteric activation of the kinase domain: A mechanism which alters the selectivity profile of oncogenic EGFR.
Presenter: Elizabeth Buck
Session: Poster Display session 1
Resources:
Abstract
5492 - Basic selective estrogen receptor degraders (B-SERDs) in combination with novel BET inhibitors in ER+ breast cancer
Presenter: Rui Xiong
Session: Poster Display session 1
Resources:
Abstract
5965 - EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer
Presenter: Ronan Le Moigne
Session: Poster Display session 1
Resources:
Abstract
3582 - AVID200 neutralizes TGF-beta1 and -beta3, the principal immunosuppressive TGF-beta isoforms overexpressed by tumors, and sensitizes tumors to immune checkpoint inhibitors.
Presenter: Tina Gruosso
Session: Poster Display session 1
Resources:
Abstract
1996 - High NAMPT expression and anti-tumor activity of NAMPT inhibitor in adult T-cell leukemia/lymphoma
Presenter: Tomohiro Kozako
Session: Poster Display session 1
Resources:
Abstract
4307 - TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers
Presenter: Alexander Drilon
Session: Poster Display session 1
Resources:
Abstract
4869 - In Vivo Evaluation of Cisplatin-loaded PEG-PCL Block Copolymeric Nanoparticles for Anticancer Drug Delivery
Presenter: Yingtzu Yen
Session: Poster Display session 1
Resources:
Abstract